N/A N=256 Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Breast Cancer · Stage IV Breast Cancer
Primary: 3-year Overall Survival Rate — 67.9; 68.4 percentage of participants — p=0.32
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=799 Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Estrogen Receptor Negative · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Progression Free Survival — 10.97; 9.3; 7.36 months — p=0.054
Phase 2 N=76 S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Survival at 1 Year — 93 percentage of patients
Phase 2 N=23 Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Evaluate Toxicity of Infusing HER2-specific T Cells as Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 — 0…
Phase 2 N=82 Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
Breast Cancer
Primary: Cardiac Toxicity of Weekly Taxol Given With Weekly Herceptin When Delivered Immediately Following Four Cycles of Standard Dose AC. — 1; 8; 3; 11 Participants
Phase 3 N=394 Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
Invasive Breast Carcinoma · Recurrent Breast Carcinoma · Stage III Breast Cancer AJCC v6
Primary: Progression-free Survival — 20.2; 15.6 months
Phase 1 N=11 Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Breast Cancer
Primary: The Number of Participants Who Experienced Dose-limiting Adverse Events — 1; 0 participants
Phase 2 N=112 S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Response Rate (Complete and Partial, Confirmed and Unconfirmed) — 29 participants
Phase 2 N=76 Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Antitumor Activity Based on Time to Tumor Progression (TTP). — 9.3 months
N/A N=20 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
Phase 2 N=36 Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 4.3 months
Phase 2 N=26 Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Phase 2 N=23 Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Phase 2 N=103 Ixabepilone + Carboplatin Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Phase 2 N=33 Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathologic Complete Response (pCR) — 6 patients
Phase 2 N=50 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Estrogen Receptor-negative Breast Cancer · Estrogen Receptor-positive Breast Cancer · Inflammatory Breast Cancer
Primary: Event-free Survival — 11; 9 Participants
Phase 3 N=129 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Phase 2 N=27 S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
Breast Cancer
Primary: Confirmed Response Rate (Complete and Partial) — 2 participants
Phase 2 N=41 Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
Breast Cancer
Primary: Three-year Relapse-free Survival — 61.5; 77.8 percentage of participants
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 3 N=295 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Estrogen Receptor Positive · HER2 Positive Breast Carcinoma · HER2/Neu Negative
Primary: Progression-free Survival (PFS) — 4.7; 3.8 months — p=0.37
N/A N=30 Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer
Breast Cancer
Primary: Acute Radiation Effects (Less Than 90 Days Post Treatment) — 0 Participants
Phase 2 N=32 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Breast Cancer
Primary: 5-Year Relapse-free Survival Rate — 53 percentage of participants
Phase 2 N=24 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
Phase 2 N=25 Partial Breast Irradiation With Chemotherapy
Breast Cancer
Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants
Phase 2 N=38 Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Recurrent Breast Carcinoma · Stage IV Breast Cancer
Primary: Level of EGFR Expression — 24; 8; 4; 0 participants
Phase 3 N=475 A Phase III Trial For Patients With Metastatic Breast Cancer
Breast Cancer · Breast Neoplasms · Cancer of the Breast
Primary: Time to Disease Progression (Initial Treatment) — 9.28; 8.88 months — p=0.385
Phase 2 N=3 Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Maximum Tolerated Dose and Optimal Tolerated Dose of Pegylated Liposomal Doxorubicin Hydrochloride (Doxil) When Given in Combination With Cyclophosphamide (Phase I) — 30…
Phase 2 N=46 Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity in Phase I — 0; 3 participants with DLTs
N/A N=15 Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Male Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECIST — 60 percentage of patients